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To the Editor
IgE antibodies (Abs) can mediate allergic reactions, including systemic anaphylaxis by 
activating the high affinity FcεRI on mast cells and basophils, leading to release of 
inflammatory mediators1,2,E1–3 (see References E1–45 in this article´s Online Repository). 
In contrast, allergen-specific IgG Abs, which are also induced by allergen-specific 
immunotherapies (AIT), can inhibit IgE-mediated anaphylaxis caused by low levels of 
allergen through allergen-masking and crosslinking of the FcεRI with the classical IgG 
inhibitory receptor FcγRIIb2,3,E1,4,5. However, when allergen levels are high, IgG Abs 
induced in untreated and SIT-treated allergic patients as well as to medical drugs also have 
the potential to mediate anaphylaxis by activating classical activating FcγRs on different 
immune cell types2,3,4,E6–12.
The effector functions of IgG Abs depend on their subclassE11,13 and the type of Fc N-
glycosylation (Fig 1, A, and Fig E1). Agalactosylated IgG Abs generally promote 
inflammationE14,15, whereas galactosylation and terminal sialylation of IgG Abs generally 
suppress inflammation5–8,E15–19. However, the effects of IgG subclass and Fc glycosylation 
pattern in allergy remain unclear.
Here, we first compared the capacity of differently glycosylated forms of murine IgG1, a 
subclass that resembles AIT-induced human IgG4 in its limited ability to activate 
complement and classical activating FcγRs3,E1,5,11,13, to inhibit IgE-mediated systemic 
anaphylaxis (Fig 1, B–E, and Fig E1 (see Figs E1–4 and Methods in this article´s Online 
Repository)). IgE-mediated anaphylaxis (assessed as decreased rectal temperature) was 
induced intravenously (i.v.) with 10 µg of IgE anti-2,4,6-trinitrophenyl (TNP) monoclonal 
Ab (mAb), followed by an i.v. challenge 24 h later with 1 µg of TNP-coupled ovalbumin 
(TNP-OVA) (Fig 1, B). Increasing doses of differently glycosylated murine IgG1 anti-TNP 
mAbs (clone H5; native=low-galactosylated (low-gal), in vitro galactosylated (gal) or in 
vitro galactosylated plus sialylated (sialylated; sial)) decreased IgE-mediated hypothermia in 
a FcγRIIb-dependent manner (Fig 1, B–E, and Fig E1).
Even though low-galactosylated IgG1 showed a tendency for more efficient inhibition (Fig 
1, C; 3 µg of IgG1; not significant), possibly due to its higher affinity than sialylated IgG1 
Epp et al. Page 2













for FcγRIIb16, the IgG glycosylation pattern (Fig 1, D and E) and IgG subclass (studied by 
comparing IgG1, IgG2a and IgG2b anti-TNP class switch variant (sv) mAbs with identical 
V(D)J sequences)E20 (Fig E1, G and data not shown) had only a slight effect on extent of 
inhibition.
In contrast, the severity of IgG-mediated systemic anaphylaxis, which required challenge 
with a higher antigen dose (20 µg)2,3, was IgG subclass- and glycosylation-dependent (Fig 1, 
G and H, and Fig E1). De-sialylated plus de-galactosylated (de-gal) IgG2a and IgG2b 
subclass anti-TNP (sv) mAbs induced more severe anaphylaxis than de-galactosylated (sv) 
and low-galactosylated (H5) IgG1 mAbs (IgG2a=IgG2b>IgG1) (Fig E1)4.
IgG1-mediated anaphylaxis was inhibited by galactosylation and especially by additional 
sialylation (Fig 1, G); sialylation also significantly reduced the anaphylaxis potential of 
IgG2b and tended to reduce that of IgG2a (Fig 1, G). Sialylation even reduced the increased 
anaphylaxis potential of IgG1 in FcγRIIb-deficient mice4 (Fig 1, H), suggesting the 
importance of additional/other inhibitory mechanisms of IgG1 sialylation, such as one 
dependent on the C-type lectin receptor, SignR1 (Fig 1, I)7,8,E17,18.
These observations suggest that AIT protocols that promote sialylation of human IgG4 
might optimally limit the possibility of IgG-mediated systemic anaphylaxis in the presence 
of higher allergen doses.
To evaluate this assumption, we analyzed how conventional AIT with birch pollen extract 
and the adjuvant aluminium hydroxide (alum) (ALK-depot SQ from ALK-Abelló) affects 
the IgG subclass and glycosylation of anti-Bet v 1 (Betula verrucosa 1; the major birch 
pollen allergen) Abs (Fig E4)9,E21–23.
In untreated patients, Bet v 1-specific IgG4 titers were constantly low, while IgE but also 
IgG1 titers increased uring the pollen season (Fig 2, A, and Fig E2). In contrast, during AIT, 
levels of Bet v 1-specific IgG1 increased in the first 12 months but decreased afterwards, 
while Bet v 1-specific IgG4 titers persistantly increased (Fig 2, A, and Fig E2)1,9,E21,22,24.
However, the Fc glycosylation profile of Bet v 1-specific serum IgG Abs from untreated and 
AIT-treated patients remained stable and were more highly galactosylated and sialylated 
than IgG autoAbs from rheumatoid arthritis (RA) patientsE14 (Fig 2, B and C, and Fig E2). 
The glycosylation profiles of the AIT-treated patients resembled those of two recently 
described AIT patients who had received similar therapy with alum (Allergovit from 
Allergopharma)5 and of those in therapeutic IVIg, which have Fc sialylation-dependent anti-
inflammatory properties (Fig 2, B and C, and Fig E2)E16–18.
Consistent with an inverse relationship between IgG sialylation and inflammatory potential, 
we found that de-sialylation of native Bet v 1-specific IgG from the serum of AIT-treated 
patients strongly increased its ability to activate neutrophils in vitro (Fig 2, B–E, and Fig 
E2).
These observations suggest that conventional AIT with alum induces sialylated IgG(4) Abs 
that probably have low potential to induce IgG-mediated allergic reactions.
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However, studies remain required to assess how Fc glycosylation modulates the effector 
functions of human IgG1 and IgG4 and how new AIT protocols with distinct 
adjuvants1,E25–29, will influence the human IgG subclass distribution and Fc glycosylation 
pattern and consequently, the risk of IgG-mediated allergic reactions.
To initiate such studies, we compared the effects of enriched complete Freund’s adjuvant 
(eCFA; highly inflammatory), alum and Monophosphoryl Lipid A (MPLA; recently 
approved for AIT)1,6,E26,27 on IgG subclass and Fc glycosylation profiles in OVA-
immunized mice (Fig 2, F, and Fig E3). eCFA induced the highest IgG titer 
(eCFA>MPLA=alum) (Fig E3, C), but all three immunizations induced predominantly IgG1 
(alum/94%>eCFA/81%>MPLA/65%) followed by IgG2b and hardly IgG2c (IgG2 (IgG2b
+IgG2c): MPLA/35%>eCFA/19%>alum/6%) (Fig 2, G, and Fig. E3, C), whose functions 
depend on galactosylation (only IgG1) and sialylation (IgG1 and at least in part IgG2b) (Fig 
1, G).
In contrast to only small differences in Fc glycosylation pattern between human IgG 
subclasses in the same sample30,31, glyopeptide analysis confirmed that murine IgG2 (IgG2b 
and IgG2c) was, on average, much more highly galactosylated and sialylated than IgG1 (Fig 
2, H, and Fig E3)32. Because alum and MPLA induced higher galactosylation and sialylation 
levels of both OVA-specific IgG1 and IgG2(b) than OVA-eCFA (Fig 2, H), MPLA, with the 
highest ratio of IgG2(b), induced the highest levels of total IgG galactosylation and 
sialylation as determined by HPLC glycan analysis (Fig 2, I, and Fig E3). Consistent, only 
100 µg of purified OVA-specific IgG Abs from the OVA-eCFA group, but not from the OVA-
MPLA group, induced IgG-mediated anaphylaxis (Fig 2, J).
Taken together, our data suggest that although IgG subclass and glycosylation pattern have 
relatively little effect on IgG Ab blocking of IgE-mediated anaphylaxis, increased sialylation 
of IgG(4) Abs should decrease the risk of IgG-induced anaphylaxis in the presence of high 
allergen doses. Accordingly, it seems advisable to select adjuvants for new AIT 
protocols1,E25,26 for their ability to promote sialylated IgG(4) Ab responses.
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FIG 1. Effect of differently glycosylated IgG subclass Abs on IgE- and IgG-mediated murine 
anaphylaxis
A, The conserved biantennary N-glycan (four N-acetylglucosamines (dark blue) and three 
mannoses (green)) at Asn 297 in the IgG Fc part can be modified by fucose (red), bisecting 
GlcNAc (light blue), galactose (G; yellow) and sialic acid (S; magenta). The cleavage site of 
EndoS used for IgG glycan analysis is depicted. B, Experimental design of IgE-mediated 
anaphylaxis as done in D and E. C, Fc glycosylation profiles of the differently glycosylated 
murine IgG1 anti-TNP mAbs (clone H5) that were used in the murine experiments; 
native=low-galactosylated (low-gal), in vitro galactosylated (gal) or galactosylated plus 
sialylated (sial). D and E, Inhibition of IgE-mediated temperature drop by differently 
glycosylated IgG1 anti-TNP mAbs (H5) in (D) wt and (E) FcγRIIb-deficient mice (in each 
graph: no IgG, n=8–10; low-gal, n=8–10; gal, n=5; sial, n=5); symbols represent means. One 
of two independent experiments is shown. F, Experimental design of IgG-mediated 
anaphylaxis as done in G–I. G–I, Decrease in body temperature induced with differently 
glycosylated IgG subclass anti-TNP mAbs in (G–I) wt or (H) FcγRIIb-deficient mice (G–I) 
without or (I) with α-SignR1 treatment; de-gal: in vitro de-sialylated plus de-galactosylated. 
(G) Pooled data (n=10–15) from independent experiments with n=5/group/experiment or 
(H, I) one of two independent experiments is shown.
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FIG 2. Bet v 1-specific serum IgG Fc glycosylation of untreated and treated allergic patients and 
influence of different adjuvants on IgG Fc glycosylation
A, Serum titers of Bet v 1-specific IgG1 and IgG4 from untreated (season, n=8; no season, 
n=6 + 11 (AIT-treated, month (m) 0)) and AIT-treated (n=11) birch pollen allergic patients; 
black line: mean; gray: pollen season. The green data points depict the 5 AIT-treated patients 
who were selected for the glycan analysis in B and C and Fig E2, while the red data points 
depict the 3 samples (patient 5 at m12 (5–12) and 5–36 and 21-18) that were chosen for in 
vitro de-sialylation and neutrophil activation in B–E and Fig E2. One of two independent 
ELISAs is shown. B and C, Percentage of (B) agalactosylated (G0) and (C) sialylated 
glycans from purified Bet v 1-specific IgG Abs of untreated (season, n=5; no season, n=5 
+ 5 (AIT-treated, m0) and the 5 selected AIT-treated patients and from IVIg and purified 
native and in vitro de-sialylated total serum IgG from patient samples 5–12, 5–36 and 21-18. 
The filled areas indicate the levels of agalactosylated (G0) or sialylated IgG autoAbs in RA 
patients for comparisonE14. D and E, Human neutrophil activation assay. (D) Experimental 
setup and (E) ROS production after activation with native or in vitro de-sialylated Bet v 1-
specific IgG Abs of patient 5 (P5 m36); no IgG (black). One of two independent ROS assays 
is shown. F–J, The effect of distinct adjuvants (eCFA, alum or MPLA) on the induction of 
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OVA-specific serum IgG Abs. F, Experimental design. G, IgG1 and IgG2 (IgG2b+IgG2c; 
both cannot be distinguished by glycopeptide analysis because of the comparable peptide 
sequence) frequencies in purified OVA-specific IgG Abs as determined by glycopeptide 
analysis. H and I, (H) IgG1 and IgG2 or (I) total IgG Fc sialylation profiles of pooled and 
purified OVA-specific IgG Abs as determined by (H) glycopeptide or (I) total IgG glycan 
analysis. J, IgG-mediated anaphylaxis as described in Fig 1, F with 100 µg of pooled and 
purified OVA-specific serum IgG Abs; n=4–5 per group. Symbols represent means.
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